Renal Osteodystrophy: Pathogenesis, Prevention and Treatment

  • Jacques J. Bourgoignie


Renal osteodystrophy is a complex disorder expressing at the musculoskeletal level the metabolic abnormalities of renal disease (1). It is universally present in patients with chronic renal disease and continues to be one of the more difficult problems that confront the clinician charged with the responsibility of managing patients with chronic renal failure. A major difficulty in attempting to adopt a rational approach in these patients’ management has been the lack of a complete understanding of the pathogenesis of the deranged skeletal metabolism (2,3). Recently, development of morphometric analysis of bone biopsies, sensitive assays of vitamin D metabolites and parathormone (PTH), specific vitamin D metabolites for experimentation combined with formulation of testable hypotheses, have expanded our understanding of calcium and phosphorus homeostasis in renal osteodystrophy. New therapeutic trends, based on recent pathophysiologic information, can be perceived which have already changed the often dramatic clinical picture seen 10–15 years ago. Treatment of renal osteodystrophy undoubtedly will undergo much refinement within the next five years and its prevention appears as a reachable goal.


Parathyroid Hormone Parathyroid Gland Secondary Hyperparathyroidism Chronic Renal Insufficiency Chronic Renal Disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kumar, B.: Renal osteodystrophy: A complex disorder. J. Lab. Clin. Med. 93: 995–897, 1979.Google Scholar
  2. 2.
    Coburn, J.W., Kurokawa, K. and Llach, F.: Altered divalent ion metabolism in renal disease and renal osteodystrophy. In: Maxwell, M.H. and Kleeman, C.R. (eds.): Clinical Disorders of Fluid and Electrolyte Metabolism. New York: McGraw Hill, 1980, pp. 1153–1251.Google Scholar
  3. 3.
    Kurokawa, K., Klein, K. and Hartenbower, D.L.: Disorders of calcium and phosphate homeostasis. In: Gonick, C. (ed.): Current Nephrology. New York: Houghton Mifflin, 1979, Vol. 3, pp. 135–197.Google Scholar
  4. 4.
    Avioli, L.V.: Renal osteodystrophy. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 142–218.Google Scholar
  5. 5.
    de Graaf, P., Schicht, I.M., Pauwels, E.K.J, et al.: Bone scintigraphy in renal osteodystrophy. J. Nucl. Med. 19: 1289–1296, 1978.PubMedGoogle Scholar
  6. 6.
    Malluche, H.H., Ritz, H., Lange, H.P. et al.: Bone histology in incipient and advanced renal failure. Kidney Int. 9: 355–372, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Dent, C.E. and Stamp, T.C.B.: Vitamin D, rickets and osteomalacia. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 237–302.Google Scholar
  8. 8.
    Bordier, P., Rasmussen, H., Marie, P. et al.: Vitamin D metabolites and bone mineralization in man. J. Clin. Endocrinol. Metab. 46: 284–294, 1978.PubMedCrossRefGoogle Scholar
  9. 9.
    Habener, J.F. and Potts, J.T., Jr.: Parathyroid physiology and primary hyperparathyroidism. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 1–149.Google Scholar
  10. 10.
    Kaplan, M.A., Canterbury, J.M., Gavallas, G. et al.: Interrelations between phosphorus, calcium, parathyroid hormone, and renal phosphate excretion in response to an oral phosphorus load in normal and uremic dogs. Kidney Int. 14: 207–214, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Reiss, E., Canterbury, J. and Kanter, A.: Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch. Int. Med. 124: 417–422, 1969.CrossRefGoogle Scholar
  12. 12.
    Slatopolsky, E., Rutherford, W.E., Hruska, K. et al.: How important is phosphate in the pathogenesis of renal osteodystrophy? Arch. Int. Med. 138: 848–852, 1978.CrossRefGoogle Scholar
  13. 13.
    Massry, S.G. The pathogenesis of secondary hyperparathyroidism of renal failure. Is there a controversy? Arch. Int. Med. 138: 848–852, 1978.CrossRefGoogle Scholar
  14. 14.
    Massry, S.G. Pathogenesis of secondary hyperparathyroidism in early renal failure: a multifactorial system including phosphate retention, skeletal resistance to PTH, and altered vitamin D metabolism. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 1203–1208.Google Scholar
  15. 15.
    Slatopolsky, E., Gray, R., Adams, N.D. et al.: The pathogenesis of secondary hyperparathyroidism in early renal failure. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 1209–1216.Google Scholar
  16. 16.
    Ritz, E., Malluche, H.H., Krempien, B. et al.: Pathogenesis of renal osteodystrophy: Roles of phosphate and skeletal resistance to PTH. In Advances in Experimental Medicine 103: 423–437, 1978.Google Scholar
  17. 17.
    Massry, S.G., Ritz, E. and Verberckmoes, R.: Role of phosphate in the genesis of secondary hyperparathyroidism of renal failure. Nephron 18: 77–81, 1977.PubMedCrossRefGoogle Scholar
  18. 18.
    Bricker, N.S., Slatopolsky, E., Reiss, E. et al.: Calcium, phosphorus and bone in renal disease and transplantation. Arch. Int. Med. 123: 543–554, 1969.CrossRefGoogle Scholar
  19. 19.
    Slatopolsky, E., Caglar, S., Pennell, J.P. et al.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J. Clin. Invest. 50: 492–500, 1971.PubMedCrossRefGoogle Scholar
  20. 20.
    Levine, B.S. and Coburn, J.W.: Physiology of the vitamin D endocrine system and disorders of altered vitamin D metabolism. In: Brenner, B.M. and Stein, J.H. (eds.): Contemporary Issues in Nephrology, Vol. 4. Hormonal Function and the Kidney. New York: Churchill Livingstone, 1979, pp. 215–251.Google Scholar
  21. 21.
    Llach, F., Massry, S.G., Singer, F.R. et al.: Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J. Clin. Endocr. Metab. 41: 339–345, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Reiss, E., Canterbury, J.M., Bercovitz, M.A. et al.: The role of phosphate in the secretion of parathyroid hormone in man. J. Clin. Invest. 49: 2146–2149, 1970.PubMedCrossRefGoogle Scholar
  23. 23.
    Rutherford, W.E., Bordier, P., Marie, P. et al.: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J. Clin. Invest. 60: 332–341, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaplan, M., Canterbury, J., Bourgoignie, J. et al.: Reversal of hyperparathyroidism in response to dietary phosphorus restriction in uremic dog. Kidney Int. 15: 43–48, 1979.PubMedCrossRefGoogle Scholar
  25. 25.
    Slatopolsky, E. and Bricker, N.S. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 4: 141–146, 1973.PubMedCrossRefGoogle Scholar
  26. 26.
    Jacob, A.I., Canterbury, J.M., Gavellas, G. et al.: Effect of Cimetidine on calcium and phosphate homeostasis in normal and uremic dogs. Clin. Res. 28, 450A, 1980.Google Scholar
  27. 27.
    Swenson, R.S., Weisinger, J.R., Ruggeri, J.L. et al.: Evidence that parathyroid hormone is not required for phosphate homeostasis in renal failure. Metab. Clin. End. 24: 199–204, 1975.Google Scholar
  28. 28.
    Tröhler, U., Bonjour, J.P. and Fleisch, H. Inorganic phosphate homeostasis. Renal adaptation to the dietary intake in intact and thyroparathyroidectomized rats. J. Clin. Invest. 57: 264–273, 1976.PubMedCrossRefGoogle Scholar
  29. 29.
    Steele, T.H. and DeLuca, F. Influence of dietary phosphorus on renal phosphate reabsorption in the parathyroidectomized rat. J. Clin. Invest. 57: 867–874, 1976.PubMedCrossRefGoogle Scholar
  30. 30.
    Sherwood, L.M., Mayer, G.P., Ramberg, C.F., Jr. et al.: Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate. Endocr. 83: 1043–1052, 1969.Google Scholar
  31. 31.
    Massry, S.G., Coburn, J.W., Lee, D.B. et al.: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann. Int. Med. 78: 357–364, 1973.PubMedGoogle Scholar
  32. 32.
    Massry, S.G., Stein, R., Garty, G. et al.: Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of l,25(OH)2D3. Kidney Int. 9: 467–474, 1976.PubMedCrossRefGoogle Scholar
  33. 33.
    Massry, S.G., Dua, S., Garty, J. et al.: Role of uremia in the skeletal resistance to the calcemic action of parathyroid hormone. Min. Electrolyte Metab. 1: 172–180, 1978.Google Scholar
  34. 34.
    Kaplan, M.A., Canterbury, J.M., Gavellas, G. et al.: The calcemic and Phosphaturie effects of parathyroid hormone in the normal and uremic dog. Metab. 27: 1785–1792, 1978.CrossRefGoogle Scholar
  35. 35.
    Massry, S.G., Tumas, S., Dua, S. and Goldstein, D.A.: Reversal of skeletal resistance to parathormone in uremia by vitamin D metabolites. J. Lab. Clin. Med. 94: 152–158, 1979.PubMedGoogle Scholar
  36. 36.
    Wills, M.R. and Jenkins, M.V.: The effect of uremic metabolites on parathyroid extract — induced bone resorption in vitro. Clin. Chim. Acta 73: 121–125, 1976.PubMedCrossRefGoogle Scholar
  37. 37.
    Raisz, L.G. and Niemann, I.: Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocr. 85: 446–453, 1969.CrossRefGoogle Scholar
  38. 38.
    Habener, J.F. and Potts, J.T.: Biosynthesis of parathyroid hormone. N. Engl. J. Med. 299: 580–585 and 635–644, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    Hruska, K.A., Kapelman, R., Rutherford, W.E. et al.: Metabolism of immunoreactive parathyroid hormone in the dog. J. Clin. Invest. 56: 39–48, 1975.PubMedCrossRefGoogle Scholar
  40. 40.
    Freitag, J.J., Martin, K., Hruska, K.A. et al.: Impaired parathyroid hormone metabolism in patients with chronic renal failure. N. Engl. J. Med. 298: 29–32, 1978.PubMedCrossRefGoogle Scholar
  41. 41.
    Martin, K., Hruska, K.A., Freitag, J.J. et al.: The peripheral metabolism of parathyroid hormone. N. Engl. J. Med. 301: 1092–1098, 1979.PubMedCrossRefGoogle Scholar
  42. 42.
    Bellorin-Font, Martin, K.J., Freitag, J.J. et al.: Altered adenylate cyclase kinetics in hyperfunctioning human glands. Comparison with normal human and bovine parathyroid tissue. J. Clin. Invest. In press.Google Scholar
  43. 43.
    Canterbury, J.M., Lerman, S., Claflin, A.J. et al.: Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25 dihydroxycholecalciferol in the dog. J. Clin. Invest. 51: 1375–1383, 1978.CrossRefGoogle Scholar
  44. 44.
    Canterbury, J.M., Gavellas, G., Bourgoignie, J. et al.: In-vivo suppression of parathyroid hormone secretion by 24,25 dihydroxycholecalciferol in hyperparathyroid dogs. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 297–305.Google Scholar
  45. 45.
    Canterbury, J., Gavellas, G., Bourgoignie, J. et al.: Metabolic consequences of oral administration of 24,25(OH)2D3 to uremic dog. J. Clin. Invest. 65: 571–576, 1980.PubMedCrossRefGoogle Scholar
  46. 46.
    Care, A.D., Pickard, D.W., Papapoulos, S.E. et al.: Inhibitory effect of 25,26-dihydroxycholecalciferol on the rate of secretion of parathyroid hormone in goats. J. Endocr. 78: 303–304, 1978.PubMedCrossRefGoogle Scholar
  47. 47.
    Golden, P., Mazey, R., Greenwalt, A. et al.: Vitamin D: A direct effect on the parathyroid gland? Min. Electrolyte Metab. 2: 1–6, 1979.Google Scholar
  48. 48.
    Tanaka, Y., DeLuca, H.F., Ghazarian, J.G. et al.: Effect of vitamin D and its metabolites on serum parathyroid hormone levels in the rat. Min. Electrolyte Metab. 2: 20–25, 1979.Google Scholar
  49. 49.
    DeLuca, H.F.: Vitamin D and calcium transport. Annals N.Y. Acad. Sci. 356–376, 1978.Google Scholar
  50. 50.
    DeLuca, H.F.: Vitamin D metabolism and function. Arch. Int. Med. 138: 836–847, 1978.CrossRefGoogle Scholar
  51. 51.
    Haussler, M.R. and McCain, T.: Basic and medical concepts related to vitamin D metabolism and action. N. Engl. J. Med. 297: 974–983 and 1041–1050, 1977.PubMedCrossRefGoogle Scholar
  52. 52.
    Taylor, C.M.: 24,25-dihydroxyvitamin D in human serum. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 197–204.Google Scholar
  53. 52a.
    Russell, R.G.G., Kanis, J.A., Smith, R. et al.: Physiological and pharmacological aspects of 24,25-dihydroxycholecalciferol in man. In: Advances in Experimental Medicine 103: 487–504, 1978.Google Scholar
  54. 53.
    Horst, R.L., Shepard, R.M., Jorgensen, N.A. et al.: Assays of vitamin D and its metabolites. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 213–220.Google Scholar
  55. 54.
    Lund, B., Clausen, E., Friedberg, M. et al.: Serum 1,25-dihydroxycholecalciferol in anephric, haemodialyzed and kidney transplanted patients. Effect of vitamin D supplement. Nephron 25–33, 1980.Google Scholar
  56. 55.
    Liu, S.H. and Chu, H.I.: Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihydrotachysterol (AT10) and iron. Medicine (Baltimore) 22: 103–162, 1943.Google Scholar
  57. 56.
    Malluche, H.H., Werner, E. and Ritz, E.: Intestinal absorption of calcium and wholebody calcium retention in incipient and advanced renal failure. Min. Electrolyte Metab. 1: 263–270, 1978.Google Scholar
  58. 57.
    Kanis, J.A., Keyner, G., Russell, R.G.G. et al.: Biological effects of 24,25-dihydroxycholecalciferol in man. In: Norman, A.W. et al. (eds.): Vitamin D. Biochemical, chemical and clinical aspects related to calcium metabolism. New York: W. de Gruyter, 1977, pp. 793–796.Google Scholar
  59. 58.
    Llach, F., Brickman, A.S., Singer, F.R. et al.: 24,25-dihydroxycholecalciferol, a vitamin D sterol with qualitatively unique effects in uremic man. Metab. Bone Dis. and Rel. Res. 2: 11–15, 1979.CrossRefGoogle Scholar
  60. 59.
    Malluche, H.H., Goldstein, D.A. and Massry, S.G. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J. Clin. Invest. 73: 494–500, 1979.CrossRefGoogle Scholar
  61. 60.
    Slatopolsky, E., Rutherford, W.E., Rosenbaum, R. et al.: Hyperphosphatemia. Clin. Nephrol. 7: 138–146, 1977.PubMedGoogle Scholar
  62. 61.
    Goldsmith, R., Furszyfer, J., Johnson, W.J. et al.: Control of secondary hyperparathyroidism during long-term hemodialysis. Am. J. Med. 50: 692–699, 1971.PubMedCrossRefGoogle Scholar
  63. 62.
    Bouillon, R., Verberckmoes, R. and DeMoor, P.: Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Kidney Int. 7: 422–432, 1975.PubMedCrossRefGoogle Scholar
  64. 63.
    Goldsmith, R.S. and Johnson, W.J. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy. Kidney Int. 4: 154–161, 1973.PubMedCrossRefGoogle Scholar
  65. 64.
    Clarkson, E.M., Eastwood, J.B., Koutsaimanis, K.G. et al.: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. 3: 258–263, 1973.PubMedCrossRefGoogle Scholar
  66. 65.
    Goldstein, D.A., Malluche, H.H. and Massry, S.G. Management of renal osteodystrophy with 1,25(OH)2D3. I. Effects on clinical, radiographic, and biochemical parameters. Min. Electrolyte Metab. 2: 35–47, 1979.Google Scholar
  67. 66.
    Malluche, H.H., Goldstein, D.A. and Massry, S. Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone: evidence for healing osteomalacia. Min. Electrolyte Metab. 2: 48–55, 1979.Google Scholar
  68. 67.
    Fournier, A., Bordier, P, Gueris, J. et al.: Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy — greater effects of 25-hydroxycholecalciferol on bone mineralization. Kidney Int. 15: 196–204, 1979.PubMedCrossRefGoogle Scholar
  69. 68.
    Hodsman, A.B., Sherrard, D.J., Wong, E.G.C. et al.: Vitamin D resistant osteomalacia without secondary hyperparathyroidism in dialysis patients. Clin. Res. 28: 560A, 1980.Google Scholar
  70. 68a.
    Coburn, J.W., Wong, E.G.C, Sherrard, D.J. et al.: Use of 24, 25-dihydroxyvitamin D3 in dialysis osteomalacia: preliminary results. Clin. Res. 28: 532A, 1980.Google Scholar
  71. 69.
    Eastwood, J.B., de Wardener, H.E., Gray, R.W. et al.: Normal plasma 1,25-(OH)2 — Vitamin-D concentrations in nutritional osteomalacia. Lancet 1: 1377–1378, 1979.PubMedCrossRefGoogle Scholar
  72. 70.
    Bell, N.H. and Stern, P.H. Hypercalcemia and increases in serum hormone value during prolonged administration of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 298: 1241–1243, 1978.PubMedCrossRefGoogle Scholar
  73. 71.
    Christiansen, C., Redbro, P., Christensen, M.S. et al.: Deterioration of renal function during treatment of chronic renal failure with 1,25 dihydroxycholecalciferol. Lancet 2: 700–703, 1978.PubMedCrossRefGoogle Scholar
  74. 72.
    Nielsen, H.E., Romer, F.K., Meisen, F. et al.: 1α-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin. Nephrol. 13: 103–108, 1980.PubMedGoogle Scholar
  75. 73.
    Wilson, R.E., Hampers, C.L., Bernstein, D.S. et al.: Subtotal parathyroidectomy in chronic renal failure. A seven year experience in a dialysis and transplant program. Ann. Surgery 174: 640–652, 1971.CrossRefGoogle Scholar
  76. 74.
    Wells, S.A., Gunnells, J.C., Shelburne, J.D. et al.: Transplantation of the parathyroid glands in man: clinical indications and results. Surgery 78: 34–43, 1975.PubMedGoogle Scholar
  77. 75.
    Schneider, A.B., Wells, S.A., Gunnells, J.C. et al.: Regulation of function of transplanted parathyroid glands. Am. J. Med. 63: 710–718, 1977.PubMedCrossRefGoogle Scholar
  78. 76.
    Cordeil, L.J., Maxwell, J.G. and Warden, G.D. Parathyroidectomy in chronic renal failure. Am. J. Surgery 138: 951–956, 1979.CrossRefGoogle Scholar
  79. 77.
    Caro, J.F., Besarab, A., Burke, J.F. et al.: A possible role for propranolol in the treatment of renal osteodystrophy. Lancet 2: 451–454, 1978.PubMedCrossRefGoogle Scholar
  80. 78.
    Coevoet, B., Andrejak, M., Desplan, C. et al.: Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uremic patients. In: Thurm, R.H. (ed.): Essential Hypertension. Chicago: Yearbook Medical Publ., 1979, pp. 219–229.Google Scholar
  81. 79.
    Caro, J.F., Castro, J.H. and Glennon, J.A.: Effect of long-term propranolol administration on parathyroid hormone and calcium concentration in primary hyperparathyroidism. Ann. Int. Med. 91: 740–741, 1979.PubMedGoogle Scholar
  82. 80.
    Jacob, A.I., Lanier, D., Jr., Canterbury, J.M. et al. Reduction of serum parathyroid hormone levels in uremic patients. N. Engl. J. Med. 302: 671–674, 1980.PubMedCrossRefGoogle Scholar
  83. 81.
    Kukreja, S.C., Williams, G.A., Hargis, G.K. et al.: Dual control of suppressibility of parathyroid hormone by calcium and by beta-adrenergic blockade. Min. Electrolyte Metab. 2: 316–322, 1979.Google Scholar
  84. 82.
    Brown, E.M., Gardner, D., Windeck, R.A. et al.: B. Adrener-gically stimulated 3f, 5f monophosphate accumulation in and parathyroid hormone release from dispersed human parathyroid cells. J. Clin. Endocr. Metab. 48: 618–626, 1976.CrossRefGoogle Scholar
  85. 83.
    Kukreja, S.C., Johnson, P.A., Ayala, G. et al.: Role of calcium and beta-adrenergic system in control of parathyroid hormone secretion. Proc. Soc. Exp. Biol. Med. 151: 326–328, 1976.PubMedGoogle Scholar
  86. 84.
    Longley, R.S., Hargis, G.K., Bowser, E.N. et al.: Parathyroid hormone and calcitonin secretion: role of histamine H2 receptors. Clin. Res. 28: 398A, 1980.Google Scholar
  87. 85.
    Brown, E.M.: Histamine receptors in parathyroid adenomas. Clin. Res. 28: 388A, 1980.Google Scholar
  88. 86.
    Williams, G.A., Longley, R.S., Hargis, G.K. et al.: Effect of histamine on secretion of parathyroid hormone. Clin. Res. 27: 794A, 1979.Google Scholar
  89. 87.
    Fischer, J.A. and Blum, J.W.: Noncalcium control of parathyroid hormone secretion. Min. Electrolyte Metab. 3: 158–166, 1980.Google Scholar
  90. 88.
    Lanier, D., Favre, H., Jacob, A.I. et al.: Cimetidine therapy for severe hypercalcemia in two chronic hemodialysis patients. Ann. Int. Med. In press.Google Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • Jacques J. Bourgoignie
    • 1
  1. 1.Div. Nephrol., Dept. Med.Univ. Miami Sch. Med.MiamiUSA

Personalised recommendations